Commenting on Synexa’s CEPI membership, Justin Devine, Co-Founder & Chief Innovation Officer at Synexa Life Sciences, said: “Synexa is proud to join the CLN, bolstering CEPI’s network in the Global South and aligning ourselves with the mission of epidemic preparedness and innovation. We are excited to contribute to this global effort to combat emerging infectious diseases and protect lives worldwide. Together, we can accelerate the development and equitable distribution of vaccines, ensuring that vulnerable populations have access to lifesaving interventions. Joining the CLN allows us to harness the power of collaboration, innovation, standardization, and solidarity, as we work towards a healthier, safer future for all.”
Emile Lens, CEO of Synexa Life Sciences, commented: “Joining CEPI symbolizes the strides Synexa has made over the last decade to become an influential, global player in the biomarker and biopharma industry. We look forward to aligning our resources and leading bioanalytical expertise with the CEPI CLN to leverage collective knowledge and aid the development and deployment of life saving vaccines all over the world”.
CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched in 2017, to develop vaccines against future epidemics. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.